Last reviewed · How we verify
NCT03471169
Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease
Phase 1 trial testing Desirable TEG in Cerebrovascular Disease in 3,500 participants. Status unknown.
1 December 2018
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 3,500 |
| Start date | 1 April 2017 |
| Primary completion | 1 December 2018 |
| Estimated completion | 1 December 2018 |
| Sites | 1 location across China |
Drugs / interventions tested
- Desirable TEG — full drug profile →
- Undesirable TEG — full drug profile →
Conditions studied
- Cerebrovascular Disease — all drugs for Cerebrovascular Disease →
Sponsor
Xuanwu Hospital, Beijing
Who can join
Adults 14 to 80, any sex, with Cerebrovascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03471169
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebrovascular Disease
Currently open trials in the same condition.
- NCT07049094 — The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy · Phase 4 · recruiting
- NCT06925178 — Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease · recruiting
- NCT06241482 — Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care · NA · recruiting
- NCT06668519 — Magnetoencephalography in Children · recruiting
- NCT06859502 — National Database of the Virtual Institute of Cerebrovascular Diseases · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03471169 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 20 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03471169.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing